;PMID: 11708799
;source_file_1867.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..55] = [t:0..55]
;1)sentence:[e:61..166] = [t:61..166]
;2)section:[e:170..279] = [t:170..279]
;3)section:[e:283..443] = [t:283..443]
;4)sentence:[e:447..669] = [t:447..669]
;5)sentence:[e:670..881] = [t:670..881]
;6)sentence:[e:882..1114] = [t:882..1114]
;7)sentence:[e:1115..1298] = [t:1115..1298]
;8)sentence:[e:1299..1579] = [t:1299..1579]
;9)sentence:[e:1580..1732] = [t:1580..1732]
;10)sentence:[e:1733..1866] = [t:1733..1866]
;11)sentence:[e:1867..2067] = [t:1867..2067]
;12)sentence:[e:2068..2192] = [t:2068..2192]
;13)sentence:[e:2193..2355] = [t:2193..2355]
;14)sentence:[e:2356..2521] = [t:2356..2521]
;15)section:[e:2522..2552] = [t:2522..2552]
;16)section:[e:2556..2601] = [t:2556..2601]

;section 0 Span:0..55
;Biochem Biophys Res Commun. 2001 Nov 23;289(1):198-204.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..15] Biophys) (NNP:[16..19] Res)
        (NNP:[20..26] Commun) (.:[26..27] .) (CD:[28..32] 2001)
        (IN:[33..36] Nov) (CD:[37..43] 23;289) (-LRB-:[43..44] -LRB-)
        (CD:[44..45] 1) (-RRB-:[45..46] -RRB-) (CD:[46..54] :198-204)
        (.:[54..55] .)))

;sentence 1 Span:61..166
;Tributyltin or triphenyltin inhibits aromatase activity in the human 
;granulosa-like tumor cell line KGN.
;[61..72]:substance:"Tributyltin"
;[76..88]:substance:"triphenyltin"
;[98..107]:substance:"aromatase"
(SENT
  (S-HLN
    (NP-SBJ (NN:[61..72] Tributyltin) (CC:[73..75] or)
            (NN:[76..88] triphenyltin))
    (VP (VBZ:[89..97] inhibits)
      (NP (NN:[98..107] aromatase) (NN:[108..116] activity))
      (PP-LOC (IN:[117..119] in)
        (NP
          (NP (DT:[120..123] the)
            (ADJP
              (NML (JJ:[124..129] human) (NN:[131..140] granulosa))
              (HYPH:[140..141] -) (JJ:[141..145] like))
            (NN:[146..151] tumor) (NN:[152..156] cell) (NN:[157..161] line))
          (NP (NN:[162..165] KGN)))))
    (.:[165..166] .)))

;section 2 Span:170..279
;Saitoh M, Yanase T, Morinaga H, Tanabe M, Mu YM, Nishi Y, Nomura M, Okabe T, 
;Goto K, Takayanagi R, Nawata H.
(SEC
  (FRAG (NNP:[170..176] Saitoh) (NNP:[177..179] M,) (NNP:[180..186] Yanase)
        (NNP:[187..188] T) (,:[188..189] ,) (NNP:[190..198] Morinaga)
        (NNP:[199..201] H,) (NNP:[202..208] Tanabe) (NNP:[209..211] M,)
        (NNP:[212..214] Mu) (NNP:[215..217] YM) (,:[217..218] ,)
        (NNP:[219..224] Nishi) (NNP:[225..226] Y) (,:[226..227] ,)
        (NNP:[228..234] Nomura) (NNP:[235..237] M,) (NNP:[238..243] Okabe)
        (NNP:[244..245] T) (,:[245..246] ,) (NNP:[248..252] Goto)
        (NNP:[253..255] K,) (NNP:[256..266] Takayanagi) (NNP:[267..268] R)
        (,:[268..269] ,) (NNP:[270..276] Nawata) (NNP:[277..279] H.)))

;section 3 Span:283..443
;Department of Medicine and Bioregulatory Science, Graduate School of Medical 
;Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, 
;Japan.
(SEC
  (FRAG (NNP:[283..293] Department) (IN:[294..296] of) (NNP:[297..305] Medicine)
        (CC:[306..309] and) (NNP:[310..323] Bioregulatory)
        (NNP:[324..331] Science) (,:[331..332] ,) (NNP:[333..341] Graduate)
        (NNP:[342..348] School) (IN:[349..351] of) (NNP:[352..359] Medical)
        (NNPS:[361..369] Sciences) (,:[369..370] ,) (NNP:[371..377] Kyushu)
        (NNP:[378..388] University) (,:[388..389] ,) (CD:[390..395] 3-1-1)
        (NNP:[396..404] Maidashi) (,:[404..405] ,) (NNP:[406..414] Higashi-)
        (NN:[414..416] ku) (,:[416..417] ,) (NNP:[418..425] Fukuoka)
        (CD:[426..434] 812-8582) (,:[434..435] ,) (NNP:[437..442] Japan)
        (.:[442..443] .)))

;sentence 4 Span:447..669
;The superimposition of male sex organs (penis and vas deferens) in a female 
;gastropod, called imposex, is widely attributed to the exposure to
;tributyltin  (TBT) compounds, used world-wide in antifouling paints for
;ships.
;[591..619]:substance:"tributyltin  (TBT) compounds"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (DT:[447..450] The) (NN:[451..466] superimposition))
        (PP (IN:[467..469] of)
          (NP
            (NP (JJ:[470..474] male) (NN:[475..478] sex) (NNS:[479..485] organs))
            (PRN (-LRB-:[486..487] -LRB-)
              (NP
                (NP (NN:[487..492] penis))
                (CC:[493..496] and)
                (NP (NN:[497..500] vas) (NN:[501..509] deferens)))
              (-RRB-:[509..510] -RRB-))))
        (PP-LOC (IN:[511..513] in)
          (NP (DT:[514..515] a) (JJ:[516..522] female) (NN:[524..533] gastropod))))
      (,:[533..534] ,)
      (VP (VBN:[535..541] called)
        (NP (-NONE-:[541..541] *))
        (NP (NN:[542..549] imposex))))
    (,:[549..550] ,)
    (VP (VBZ:[551..553] is)
      (ADVP (RB:[554..560] widely))
      (VP (VBN:[561..571] attributed)
        (NP-1 (-NONE-:[571..571] *))
        (PP-CLR (TO:[572..574] to)
          (NP
            (NP (DT:[575..578] the) (NN:[579..587] exposure))
            (PP (TO:[588..590] to)
              (NP
                (NP
                  (NML
                    (NML (NN:[591..602] tributyltin))
                    (NML (-LRB-:[604..605] -LRB-) (NN:[605..608] TBT)
                         (-RRB-:[608..609] -RRB-)))
                  (NNS:[610..619] compounds))
                (,:[619..620] ,)
                (VP (VBN:[621..625] used)
                  (NP (-NONE-:[625..625] *))
                  (ADVP-LOC (NN:[626..631] world) (HYPH:[631..632] -)
                            (RB:[632..636] wide))
                  (PP-LOC (IN:[637..639] in)
                    (NP
                      (NP (JJ:[640..651] antifouling) (NNS:[652..658] paints))
                      (PP (IN:[659..662] for)
                        (NP (NNS:[663..668] ships))))))))))))
    (.:[668..669] .)))

;sentence 5 Span:670..881
;It has been  hypothesized that the TBT-induced imposex is mediated by an
;increasing androgen  level relative to the estrogen level, namely a decreased
;conversion of androgens  to estrogens (i.e., aromatization).
;[705..708]:substance:"TBT"
;[754..762]:substance:"androgen"
;[786..794]:substance:"estrogen"
;[835..844]:substance:"androgens"
;[849..858]:substance:"estrogens"
(SENT
  (S
    (NP-SBJ-2
      (NP (PRP:[670..672] It))
      (SBAR-3 (-NONE-:[672..672] *ICH*)))
    (VP (VBZ:[673..676] has)
      (VP (VBN:[677..681] been)
        (VP (VBN:[683..695] hypothesized)
          (NP-2 (-NONE-:[695..695] *))
          (SBAR-3 (IN:[696..700] that)
            (S
              (NP-SBJ-1 (DT:[701..704] the)
                (ADJP (NN:[705..708] TBT) (HYPH:[708..709] -)
                      (VBN:[709..716] induced))
                (NN:[717..724] imposex))
              (VP (VBZ:[725..727] is)
                (VP (VBN:[728..736] mediated)
                  (NP-1 (-NONE-:[736..736] *))
                  (PP (IN:[737..739] by)
                    (NP-LGS
                      (NP (DT:[740..742] an) (VBG:[743..753] increasing)
                          (NN:[754..762] androgen) (NN:[764..769] level))
                      (ADJP (JJ:[770..778] relative)
                        (PP (TO:[779..781] to)
                          (NP
                            (NP (DT:[782..785] the) (NN:[786..794] estrogen)
                                (NN:[795..800] level))
                            (,:[800..801] ,)
                            (NP
                              (ADVP (RB:[802..808] namely))
                              (NP
                                (NP (DT:[809..810] a) (VBN:[811..820] decreased)
                                    (NN:[821..831] conversion))
                                (PP (IN:[832..834] of)
                                  (NP (NNS:[835..844] androgens)))
                                (PP (TO:[846..848] to)
                                  (NP (NNS:[849..858] estrogens))))
                              (PRN (-LRB-:[859..860] -LRB-)
                                (NP
                                  (ADVP (FW:[860..864] i.e.))
                                  (,:[864..865] ,)
                                  (NP (NN:[866..879] aromatization)))
                                (-RRB-:[879..880] -RRB-)))))))))))))))
    (.:[880..881] .)))

;sentence 6 Span:882..1114
;In the present study, we tested this  hypothesis by examining the effects of
;TBT or triphenyltin (TPT) on the  aromatase activity in a cultured human
;granulosa-like tumor cell line, KGN,  which was recently established by our
;group.
;[959..962]:substance:"TBT"
;[966..978]:substance:"triphenyltin"
;[980..983]:substance:"TPT"
;[993..1002]:substance:"aromatase"
(SENT
  (S
    (PP (IN:[882..884] In)
      (NP (DT:[885..888] the) (JJ:[889..896] present) (NN:[897..902] study)))
    (,:[902..903] ,)
    (NP-SBJ (PRP:[904..906] we))
    (VP (VBD:[907..913] tested)
      (NP (DT:[914..918] this) (NN:[920..930] hypothesis))
      (PP-MNR (IN:[931..933] by)
        (S-NOM
          (NP-SBJ (-NONE-:[933..933] *))
          (VP (VBG:[934..943] examining)
            (NP
              (NP (DT:[944..947] the) (NNS:[948..955] effects))
              (PP (IN:[956..958] of)
                (NP
                  (NP (NN:[959..962] TBT))
                  (CC:[963..965] or)
                  (NP
                    (NP (NN:[966..978] triphenyltin))
                    (NP (-LRB-:[979..980] -LRB-) (NN:[980..983] TPT)
                        (-RRB-:[983..984] -RRB-))))))
            (PP (IN:[985..987] on)
              (NP (DT:[988..991] the) (NN:[993..1002] aromatase)
                  (NN:[1003..1011] activity)))
            (PP-LOC (IN:[1012..1014] in)
              (NP
                (NP
                  (NP (DT:[1015..1016] a) (VBN:[1017..1025] cultured)
                      (JJ:[1026..1031] human)
                    (ADJP (NN:[1032..1041] granulosa) (HYPH:[1041..1042] -)
                          (JJ:[1042..1046] like))
                    (NN:[1047..1052] tumor) (NN:[1053..1057] cell)
                     (NN:[1058..1062] line))
                  (,:[1062..1063] ,)
                  (NP (NN:[1064..1067] KGN)))
                (,:[1067..1068] ,)
                (SBAR
                  (WHNP-1 (WDT:[1070..1075] which))
                  (S
                    (NP-SBJ-1 (-NONE-:[1075..1075] *T*))
                    (VP (VBD:[1076..1079] was)
                      (ADVP-TMP (RB:[1080..1088] recently))
                      (VP (VBN:[1089..1100] established)
                        (NP-1 (-NONE-:[1100..1100] *))
                        (PP (IN:[1101..1103] by)
                          (NP-LGS (PRP$:[1104..1107] our)
                                  (NN:[1108..1113] group)))))))))))))
    (.:[1113..1114] .)))

;sentence 7 Span:1115..1298
;Treatment with more than 1000 ng/ml  TBT compounds was very toxic to the
;cells and caused immediate cell death within  24 h, while 200 ng/ml was found
;to cause apoptosis of the cells.
;[1140..1144]:quantitative-value:"1000"
;[1145..1165]:quantitative-units:"ng/ml  TBT compounds"
;[1234..1236]:quantitative-value:"24"
;[1237..1238]:quantitative-units:"h"
;[1246..1249]:quantitative-value:"200"
;[1250..1255]:quantitative-units:"ng/ml"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1115..1124] Treatment))
      (PP (IN:[1125..1129] with)
        (NP
          (NP
            (NP
              (QP (JJR:[1130..1134] more) (IN:[1135..1139] than)
                  (CD:[1140..1144] 1000))
              (NN:[1145..1147] ng))
            (PP (SYM:[1147..1148] /)
              (NP (NN:[1148..1150] ml))))
          (NP (NN:[1152..1155] TBT) (NNS:[1156..1165] compounds)))))
    (VP
      (VP (VBD:[1166..1169] was)
        (ADJP-PRD (RB:[1170..1174] very) (JJ:[1175..1180] toxic)
          (PP (TO:[1181..1183] to)
            (NP (DT:[1184..1187] the) (NNS:[1188..1193] cells)))))
      (CC:[1194..1197] and)
      (VP (VBD:[1198..1204] caused)
        (NP (JJ:[1205..1214] immediate) (NN:[1215..1219] cell)
            (NN:[1220..1225] death))
        (PP-TMP (IN:[1226..1232] within)
          (NP (CD:[1234..1236] 24) (NN:[1237..1238] h))))
      (,:[1238..1239] ,)
      (SBAR-ADV (IN:[1240..1245] while)
        (S
          (NP-SBJ-1
            (NP (CD:[1246..1249] 200) (NN:[1250..1252] ng))
            (PP (SYM:[1252..1253] /)
              (NP (NN:[1253..1255] ml))))
          (VP (VBD:[1256..1259] was)
            (VP (VBN:[1260..1265] found)
              (S
                (NP-SBJ-1 (-NONE-:[1265..1265] *))
                (VP (TO:[1266..1268] to)
                  (VP (VB:[1269..1274] cause)
                    (NP
                      (NP (NN:[1275..1284] apoptosis))
                      (PP (IN:[1285..1287] of)
                        (NP (DT:[1288..1291] the) (NNS:[1292..1297] cells))))))))))))
    (.:[1297..1298] .)))

;sentence 8 Span:1299..1579
;Treatment of  the KGN cells for more than 48 h with 20 ng/ml TBT or TPT,
;which is a  concentration level reported to cause imposex in marine species,
;did not affect  cell proliferation but significantly suppressed the aromatase
;activity  determined by a [(3)H]H(2)O release assay.
;[1341..1343]:quantitative-value:"48"
;[1344..1345]:quantitative-units:"h"
;[1351..1353]:quantitative-value:"20"
;[1354..1363]:quantitative-units:"ng/ml TBT"
;[1354..1359]...[1367..1370]:quantitative-units:"ng/ml"..."TPT"
;[1517..1526]:substance:"aromatase"
;[1553..1564]:substance:"[(3)H]H(2)O"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1299..1308] Treatment))
      (PP (IN:[1309..1311] of)
        (NP (DT:[1313..1316] the) (NN:[1317..1320] KGN) (NNS:[1321..1326] cells)))
      (PP-TMP (IN:[1327..1330] for)
        (NP
          (QP (JJR:[1331..1335] more) (IN:[1336..1340] than)
              (CD:[1341..1343] 48))
          (NN:[1344..1345] h)))
      (PP-MNR (IN:[1346..1350] with)
        (NP
          (NP
            (NP
              (NP (CD:[1351..1353] 20) (NN:[1354..1356] ng))
              (PP (SYM:[1356..1357] /)
                (NP (NN:[1357..1359] ml))))
            (NP (NN:[1360..1363] TBT) (CC:[1364..1366] or) (NN:[1367..1370] TPT)))
          (,:[1370..1371] ,)
          (SBAR
            (WHNP-1 (WDT:[1372..1377] which))
            (S
              (NP-SBJ-1 (-NONE-:[1377..1377] *T*))
              (VP (VBZ:[1378..1380] is)
                (NP-PRD
                  (NP (DT:[1381..1382] a) (NN:[1384..1397] concentration)
                      (NN:[1398..1403] level))
                  (VP (VBN:[1404..1412] reported)
                    (S
                      (NP-SBJ (-NONE-:[1412..1412] *))
                      (VP (TO:[1413..1415] to)
                        (VP (VB:[1416..1421] cause)
                          (NP (NN:[1422..1429] imposex))
                          (PP-LOC (IN:[1430..1432] in)
                            (NP (JJ:[1433..1439] marine)
                                (NNS:[1440..1447] species))))))))))))))
    (,:[1447..1448] ,)
    (VP
      (VP (VBD:[1449..1452] did) (RB:[1453..1456] not)
        (VP (VB:[1457..1463] affect)
          (NP (NN:[1465..1469] cell) (NN:[1470..1483] proliferation))))
      (CC:[1484..1487] but)
      (VP
        (ADVP (RB:[1488..1501] significantly))
        (VBD:[1502..1512] suppressed)
        (NP
          (NP (DT:[1513..1516] the) (NN:[1517..1526] aromatase)
              (NN:[1527..1535] activity))
          (VP (VBN:[1537..1547] determined)
            (NP (-NONE-:[1547..1547] *))
            (PP (IN:[1548..1550] by)
              (NP-LGS (DT:[1551..1552] a)
                      (NN:[1553..1564] -LSB--LRB-3-RRB-H-RSB-H-LRB-2-RRB-O)
                      (NN:[1565..1572] release) (NN:[1573..1578] assay)))))))
    (.:[1578..1579] .)))

;sentence 9 Span:1580..1732
;Treatment with 20 ng/ml TBT compounds  for 7 days also resulted in a
;reduction of the E2 production from Delta  4-androstenedione stimulated by
;db-cAMP.
;[1595..1597]:quantitative-value:"20"
;[1598..1617]:quantitative-units:"ng/ml TBT compounds"
;[1623..1624]:quantitative-value:"7"
;[1625..1629]:quantitative-units:"days"
;[1666..1668]:substance:"E2"
;[1685..1709]:substance:"Delta  4-androstenedione"
;[1724..1731]:substance:"db-cAMP"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1580..1589] Treatment))
      (PP (IN:[1590..1594] with)
        (NP
          (NP (CD:[1595..1597] 20) (NN:[1598..1600] ng))
          (PP (SYM:[1600..1601] /)
            (NP (NN:[1601..1603] ml)))
          (NP (NN:[1604..1607] TBT) (NNS:[1608..1617] compounds))))
      (PP (IN:[1619..1622] for)
        (NP (CD:[1623..1624] 7) (NNS:[1625..1629] days))))
    (ADVP (RB:[1630..1634] also))
    (VP (VBD:[1635..1643] resulted)
      (PP-CLR (IN:[1644..1646] in)
        (NP
          (NP (DT:[1647..1648] a) (NN:[1649..1658] reduction))
          (PP (IN:[1659..1661] of)
            (NP
              (NP
                (NP (DT:[1662..1665] the) (NN:[1666..1668] E2)
                    (NN:[1669..1679] production))
                (PP (IN:[1680..1684] from)
                  (NP (SYM:[1685..1690] Delta)
                      (NN:[1692..1709] 4-androstenedione))))
              (VP (VBN:[1710..1720] stimulated)
                (NP (-NONE-:[1720..1720] *))
                (PP (IN:[1721..1723] by)
                  (NP-LGS (NN:[1724..1731] db-cAMP)))))))))
    (.:[1731..1732] .)))

;sentence 10 Span:1733..1866
;The changes in the aromatase activity  by TBT compounds were associated with
;comparable changes in P450arom mRNA  assessed by RT-PCR.
;[1752..1761]:substance:"aromatase"
;[1775..1788]:substance:"TBT compounds"
;[1832..1845]:substance:"P450arom mRNA"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1733..1736] The) (NNS:[1737..1744] changes))
      (PP (IN:[1745..1747] in)
        (NP (DT:[1748..1751] the) (NN:[1752..1761] aromatase)
            (NN:[1762..1770] activity)))
      (PP (IN:[1772..1774] by)
        (NP (NN:[1775..1778] TBT) (NNS:[1779..1788] compounds))))
    (VP (VBD:[1789..1793] were)
      (VP (VBN:[1794..1804] associated)
        (NP-1 (-NONE-:[1804..1804] *))
        (PP-CLR (IN:[1805..1809] with)
          (NP
            (NP
              (NP (JJ:[1810..1820] comparable) (NNS:[1821..1828] changes))
              (PP (IN:[1829..1831] in)
                (NP (NN:[1832..1840] P450arom) (NN:[1841..1845] mRNA))))
            (VP (VBN:[1847..1855] assessed)
              (NP (-NONE-:[1855..1855] *))
              (PP-MNR (IN:[1856..1858] by)
                (NP (NN:[1859..1861] RT) (HYPH:[1861..1862] -)
                    (NN:[1862..1865] PCR))))))))
    (.:[1865..1866] .)))

;sentence 11 Span:1867..2067
;The luciferase activity of the P450arom promoter II (1 kb)  decreased after
;the addition of 20 ng/ml TBT compounds in transfected KGN cells  either in a
;basic state or in states stimulated by db-cAMP.
;[1871..1881]:substance:"luciferase"
;[1898..1906]:cyp450:"P450arom"
;[1907..1918]:substance:"promoter II"
;[1920..1921]:quantitative-value:"1"
;[1922..1924]:quantitative-units:"kb"
;[1959..1961]:quantitative-value:"20"
;[1962..1981]:quantitative-units:"ng/ml TBT compounds"
;[2059..2066]:substance:"db-cAMP"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1867..1870] The) (NN:[1871..1881] luciferase)
          (NN:[1882..1890] activity))
      (PP (IN:[1891..1893] of)
        (NP
          (NP (DT:[1894..1897] the) (NN:[1898..1906] P450arom)
             (NN:[1907..1915] promoter) (CD:[1916..1918] II))
          (PRN (-LRB-:[1919..1920] -LRB-)
            (NP (CD:[1920..1921] 1) (NN:[1922..1924] kb))
            (-RRB-:[1924..1925] -RRB-)))))
    (VP (VBD:[1927..1936] decreased)
      (PP-TMP (IN:[1937..1942] after)
        (NP
          (NP (DT:[1943..1946] the) (NN:[1947..1955] addition))
          (PP (IN:[1956..1958] of)
            (NP
              (NP
                (NP
                  (NP (CD:[1959..1961] 20) (NN:[1962..1964] ng))
                  (PP (SYM:[1964..1965] /)
                    (NP (NN:[1965..1967] ml))))
                (NP (NN:[1968..1971] TBT) (NNS:[1972..1981] compounds)))
              (PP (IN:[1982..1984] in)
                (NP (VBN:[1985..1996] transfected) (NN:[1997..2000] KGN)
                    (NNS:[2001..2006] cells)))
              (PP (CC:[2008..2014] either)
                (PP (IN:[2015..2017] in)
                  (NP (DT:[2018..2019] a) (JJ:[2020..2025] basic)
                      (NN:[2026..2031] state)))
                (CC:[2032..2034] or)
                (PP (IN:[2035..2037] in)
                  (NP
                    (NP (NNS:[2038..2044] states))
                    (VP (VBN:[2045..2055] stimulated)
                      (NP (-NONE-:[2055..2055] *))
                      (PP (IN:[2056..2058] by)
                        (NP-LGS (NN:[2059..2066] db-cAMP))))))))))))
    (.:[2066..2067] .)))

;sentence 12 Span:2068..2192
;The Ad4BP-dependent  increase in the luciferase activity of P450arom promoter
;II was also  downregulated by such treatments.
;[2072..2077]:substance:"Ad4BP"
;[2105..2115]:substance:"luciferase"
;[2128..2136]:cyp450:"P450arom"
;[2137..2148]:substance:"promoter II"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[2068..2071] The)
        (ADJP (NN:[2072..2077] Ad4BP) (HYPH:[2077..2078] -)
              (JJ:[2078..2087] dependent))
        (NN:[2089..2097] increase))
      (PP (IN:[2098..2100] in)
        (NP
          (NP (DT:[2101..2104] the) (NN:[2105..2115] luciferase)
              (NN:[2116..2124] activity))
          (PP (IN:[2125..2127] of)
            (NP (NN:[2128..2136] P450arom)
               (NN:[2137..2145] promoter) (CD:[2146..2148] II))))))
    (VP (VBD:[2149..2152] was)
      (ADVP (RB:[2153..2157] also))
      (VP (VBN:[2159..2172] downregulated)
        (NP-1 (-NONE-:[2172..2172] *))
        (PP (IN:[2173..2175] by)
          (NP-LGS (JJ:[2176..2180] such) (NNS:[2181..2191] treatments)))))
    (.:[2191..2192] .)))

;sentence 13 Span:2193..2355
;These results indicate that TBT compounds  inhibited the aromatase activity
;and also decreased the P450arom mRNA level at  the transcriptional level in
;KGN cells.
;[2221..2234]:substance:"TBT compounds"
;[2250..2259]:substance:"aromatase"
;[2292..2305]:substance:"P450arom mRNA"
(SENT
  (S
    (NP-SBJ (DT:[2193..2198] These) (NNS:[2199..2206] results))
    (VP (VBP:[2207..2215] indicate)
      (SBAR (IN:[2216..2220] that)
        (S
          (NP-SBJ-1 (NN:[2221..2224] TBT) (NNS:[2225..2234] compounds))
          (VP
            (VP (VBD:[2236..2245] inhibited)
              (NP (DT:[2246..2249] the) (NN:[2250..2259] aromatase)
                  (NN:[2260..2268] activity)))
            (CC:[2269..2272] and)
            (VP
              (ADVP (RB:[2273..2277] also))
              (VBD:[2278..2287] decreased)
              (NP-1 (-NONE-:[2287..2287] *))
              (NP (DT:[2288..2291] the)
                (NML (NN:[2292..2300] P450arom) (NN:[2301..2305] mRNA))
                (NN:[2306..2311] level))
              (PP (IN:[2312..2314] at)
                (NP (DT:[2316..2319] the) (JJ:[2320..2335] transcriptional)
                    (NN:[2336..2341] level)))
              (PP-LOC (IN:[2342..2344] in)
                (NP (NN:[2345..2348] KGN) (NNS:[2349..2354] cells))))))))
    (.:[2354..2355] .)))

;sentence 14 Span:2356..2521
;The direct inhibitory effect of TBT  compounds on the aromatase activity may
;therefore partly explain the induction  of imposex by these compounds in
;female species.
;[2388..2402]:substance:"TBT  compounds"
;[2410..2419]:substance:"aromatase"
;[2493..2502]:substance:"compounds"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2356..2359] The) (JJ:[2360..2366] direct)
          (JJ:[2367..2377] inhibitory) (NN:[2378..2384] effect))
      (PP (IN:[2385..2387] of)
        (NP (NN:[2388..2391] TBT) (NNS:[2393..2402] compounds)))
      (PP (IN:[2403..2405] on)
        (NP (DT:[2406..2409] the) (NN:[2410..2419] aromatase)
            (NN:[2420..2428] activity))))
    (VP (MD:[2429..2432] may)
      (ADVP (RB:[2433..2442] therefore))
      (ADVP (RB:[2443..2449] partly))
      (VP (VB:[2450..2457] explain)
        (NP
          (NP (DT:[2458..2461] the) (NN:[2462..2471] induction))
          (PP (IN:[2473..2475] of)
            (NP (NN:[2476..2483] imposex)))
          (PP (IN:[2484..2486] by)
            (NP (DT:[2487..2492] these) (NNS:[2493..2502] compounds)))
          (PP-LOC (IN:[2503..2505] in)
            (NP (JJ:[2506..2512] female) (NNS:[2513..2520] species))))))
    (.:[2520..2521] .)))

;section 15 Span:2522..2552
;Copyright 2001 Academic Press.
(SEC
  (FRAG (NN:[2522..2531] Copyright) (CD:[2532..2536] 2001)
        (NNP:[2537..2545] Academic) (NNP:[2546..2551] Press) (.:[2551..2552] .)))

;section 16 Span:2556..2601
;PMID: 11708799 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2556..2560] PMID) (::[2560..2561] :) (CD:[2562..2570] 11708799)
        (NN:[2571..2572] -LSB-) (NNP:[2572..2578] PubMed) (::[2579..2580] -)
        (NN:[2581..2588] indexed) (IN:[2589..2592] for)
        (NNP:[2593..2601] MEDLINE-RSB-)))
